LeadIQ logo
Learn more at LeadIQ.com

Insights

Immunomodulating Cancer Therapies BeyondSpring Pharmaceuticals focuses on developing innovative cancer therapies, such as plinabulin, to improve clinical outcomes for patients with high unmet medical needs. The success of their lead asset in clinical trials presents a significant sales opportunity for targeting oncology departments in hospitals and cancer treatment centers.

Breakthrough Status and Positive Phase 3 Data The Breakthrough status received by BeyondSpring for plinabulin in the U.S. and China, along with the positive Phase 3 data demonstrating efficacy in preventing chemotherapy-induced neutropenia, positions the company as a reputable player in the cancer therapy market. Leveraging these achievements can support sales efforts in engaging with key opinion leaders and medical institutions seeking advanced oncology treatments.

Expansion of Board of Directors The strategic appointments of Mark Santos and Brendan Delaney to BeyondSpring's Board of Directors indicate a focus on strengthening leadership and expertise in the pharmaceutical industry. This expansion opens doors for potential collaborations, partnerships, and sales opportunities with key stakeholders, including investors, industry influencers, and other pharmaceutical companies.

Recent Drug Applications Submission The recent submission of new drug applications for Plinabulin as a treatment for the prevention of chemotherapy-induced neutropenia presents a timely sales opportunity for engaging with regulatory bodies, healthcare providers, and oncology specialists. Proactive engagement with these entities can pave the way for future product adoption and market penetration.

Market Positioning and Competitive Landscape Analyzing BeyondSpring's market positioning against similar companies like Amneal Pharmaceuticals, Amgen, and others allows for a strategic approach in identifying potential sales differentiators. Understanding competitive landscapes, market trends, and customer needs can guide sales development representatives in crafting targeted sales strategies and value propositions to drive business growth and market expansion.

Similar companies to BeyondSpring

BeyondSpring Tech Stack

BeyondSpring uses 8 technology products and services including Drupal, Microsoft Word, Google Font API, and more. Explore BeyondSpring's tech stack below.

  • Drupal
    Content Management System
  • Microsoft Word
    Editors
  • Google Font API
    Font Scripts
  • Twitter Emoji (Twemoji)
    Font Scripts
  • Backbone.js
    Javascript Frameworks
  • React
    Javascript Frameworks
  • New Relic
    Real User Monitoring
  • Google Tag Manager
    Tag Management

Media & News

BeyondSpring's Email Address Formats

BeyondSpring uses at least 1 format(s):
BeyondSpring Email FormatsExamplePercentage
FLast@beyondspringpharma.comJDoe@beyondspringpharma.com
82%
First.Last@beyondspringpharma.comJohn.Doe@beyondspringpharma.com
9%
Last@beyondspringpharma.comDoe@beyondspringpharma.com
8%
First@beyondspringpharma.comJohn@beyondspringpharma.com
1%

Frequently Asked Questions

Where is BeyondSpring's headquarters located?

Minus sign iconPlus sign icon
BeyondSpring's main headquarters is located at 28 Liberty Street New York, NY 10005 US. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is BeyondSpring's phone number?

Minus sign iconPlus sign icon
You can contact BeyondSpring's main corporate office by phone at +1-646-305-6387. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is BeyondSpring's stock symbol?

Minus sign iconPlus sign icon
BeyondSpring is a publicly traded company; the company's stock symbol is BYSI.

What is BeyondSpring's official website and social media links?

Minus sign iconPlus sign icon
BeyondSpring's official website is beyondspringpharma.com and has social profiles on LinkedIn.

How much revenue does BeyondSpring generate?

Minus sign iconPlus sign icon
As of July 2024, BeyondSpring's annual revenue reached $3.8M.

What is BeyondSpring's SIC code NAICS code?

Minus sign iconPlus sign icon
BeyondSpring's SIC code is 5122 - Drugs, Drug Proprietaries, and Druggists' Sundries NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does BeyondSpring have currently?

Minus sign iconPlus sign icon
As of July 2024, BeyondSpring has approximately 48 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Chief Scientific Officer: J. T.Chief Financial Officer: Y. C.Vice President Medical Affairs: P. P.. Explore BeyondSpring's employee directory with LeadIQ.

What industry does BeyondSpring belong to?

Minus sign iconPlus sign icon
BeyondSpring operates in the Pharmaceutical Manufacturing industry.

What technology does BeyondSpring use?

Minus sign iconPlus sign icon
BeyondSpring's tech stack includes DrupalMicrosoft WordGoogle Font APITwitter Emoji (Twemoji)Backbone.jsReactNew RelicGoogle Tag Manager.

What is BeyondSpring's email format?

Minus sign iconPlus sign icon
BeyondSpring's email format typically follows the pattern of . Find more BeyondSpring email formats with LeadIQ.
BeyondSpring

BeyondSpring

Pharmaceutical ManufacturingNew York, United States11-50 Employees

BeyondSpring Pharmaceuticals is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes. The Company is developing treatments in two of the world’s largest markets, China and the United States. BeyondSpring’s first-in-class lead asset plinabulin, a selective immunomodulating microtubule-binding agent, is being developed as a “pipeline in a drug” with potential to be an anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). In the DUBLIN-3 Phase 3 study, the plinabulin and docetaxel combination met the primary endpoint of extending overall survival, compared to docetaxel alone in 2nd/3rd line non-small cell lung cancer (EGFR wild type). In addition, the plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data, for which it received Breakthrough status in the U.S. and China. Plinabulin is also currently being studied as part of other immuno-oncology (IO) combination regimens that include radiation and/or checkpoint inhibitors for the treatment of a number of cancers. Lastly, BeyondSpring also has three preclinical IO assets and majority ownership in its subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Section iconCompany Overview

Headquarters
28 Liberty Street New York, NY 10005 US
Phone number
+1-646-305-6387
SIC Code
5122 - Drugs, Drug Proprietaries, and Druggists' Sundries
Stock Symbol
BYSI
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
11-50

Section iconFunding & Financials

  • $10M

    BeyondSpring's revenue is in the range of $10M

Section iconFunding & Financials

  • $10M

    BeyondSpring's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.